Simcere Pharmaceutical Group (先声药业) has successfully completed a Phase IV clinical trial of Endostar, its patented cancer drug, in patients with non-small cell lung cancer (NSCLC). Endostar, a Class-1 drug with an anti-angiogenesis mechanism, was approved by the SFDA in 2005 to treat NSCLC. Simcere said the drug, which was administered as an adjunct to chemotherapy, “significantly” improved outcomes without causing additional adverse effects. More details...

Stock Symbol: (NYSE: SCR)